Cipla and Roche India have launched an antibody drug cocktail in India for treating mild to moderate COVID-19 cases. The antibody drug cocktail will be available at leading hospitals and Covid treatment centers across the country. The price of each patient dose will be Rs 59,750. V Simpson Emmanuel, Managing Director & CEO, Roche Pharma India tells NDTV "the antibody cocktail is a combination of two antibodies, it is effective against various variants. Clinical trials have showed it reduced the risk of hospitalisation & deaths by almost 70%."